+44-7360-538437STAGE SPECIFIC DIFFERENTIATION OF WHARTON JELLY DERIVED MESENCHYMAL STEM CELLS TO GENERATE HIGH QUALITY NEURONS
Joint Event on International Conference on CARDIOLOGY AND CARDIOVASCULAR MEDICINE & International Conference on STEM CELLS AND REGENERATIVE MEDICINE
June 18-19, 2018 | Osaka, Japan
Zaffar Equbal
National Institute of Immunology, India
Posters & Accepted Abstracts : Biomed Res
DOI: 10.4066/biomedicalresearch-C2-006
Abstract:
Neurodegenerative disorders of the central nervous system (CNS) remain as one of the major health concern, accounting for more than 10% of deaths due to different diseases. In neurodegenerative disorders, Alzheimer’s disease, Parkinson’s disease (PD), Amyotrophic lateral sclerosis (ALS), Multiple system atrophy (MSA) and Huntington disease are the major contributors. The current therapy, which involves medication and deep brain stimulation at advance stage, focuses on symptomatic treatment with none of them being able to counteract the progression of the disease. Keeping in mind the limitations associated with the present treatments, study of cell based therapy has been initiated. In this study we have successfully trans-differentiated Wharton Jelly derived mesenchymal Stem cells (WJ-MSCs) into neuronal fate. WJ-MSCs were chosen for the study because of their hypoimmunogenic, immunomodulatory, and non-tumorigenic property. WJMSCs upon treatment with FGF-2 and EGF acquired neuroectodermal fate. Further analysis of these cells confirmed drastic decrease in the expression of MSCs related genes with concomitant expressing of SOX1, the important transcription factor involved in neural fate determination. Moreover, there was a drastic reduction in the number of cells expressing CD73 and CD105, pan-markers of MSCs. These neuroectodermal cells where further induced and differentiated into mature neuronal cells.
PDF HTML